The FDA approved eribulin for treatment of advanced liposarcoma based on data from a phase III study showing that it increased overall survival by about 7 months compared with a commonly used chemotherapy, dacarbazine.
from Cancer via ola Kala on Inoreader http://ift.tt/21XkN6f
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου